Oncology Market Expertise and Global Contacts   I  Accredited CME for Oncologists  I   Provider Number: CPDSO 50212

Skip to navigation Skip to content
Oncology Market Expertise

Oncology Commercial Services

  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact
  • Home
  • About
  • Engage Oncologists
  • Investors & Lenders
  • Market Access & BD
  • Distributors and manufacturers
  • International Market Entry
  • In/Out-licensing DD
  • Market Intelligence
  • Advisory Boards
  • Medical Education & Training
  • Recruitment
  • News
  • Contact

Scientists create a renewable source of cancer-fighting T cells

By Richard Hindle

A study by UCLA researchers is the first to demonstrate a technique for coaxing pluripotent stem cells – which can give rise to every cell type in the body and which can be grown indefinitely in the lab – into becoming mature T cells capable of killing tumour cells.

Read More

No substantial benefit from transplantation reported for a high-risk leukaemia subtype

By Richard Hindle

Checking for minimal residual disease early in treatment can help some young high-risk leukaemia patients avoid bone marrow transplantation without compromising their long-term survival.

Read More

Scientist identifies gene responsible for spread of prostate cancer

By Richard Hindle

A Rutgers study has found that a specific gene in cancerous prostate tumours indicates when patients are at high-risk for the cancer to spread, suggesting that targeting this gene can help patients live longer.

Read More

New study identifies specific obesity-related risk factors for kidney cancer

By Richard Hindle

A new study confirms the long-suspected role of obesity as a risk factor for developing renal cell carcinoma (RCC), a type of kidney cancer, and identifies several specific obesity-related factors.

Read More

Scientists developing new tools for diagnosing cancer

By Richard Hindle

A group of scientists from Russia’s Ural Federal University, headed by Professor Grigory Zyryanov, synthesised a group of multi-purpose fluorophores.

Read More

New PET probe could improve detection of primary and metastatic melanoma

By Richard Hindle

A new nuclear medicine method for detecting malignant melanoma, one of the most aggressive skin cancers, has been successfully tested for the first time in humans and could improve detection of both primary and metastatic melanoma.

Read More

New combination blood test for pancreatic cancer may catch disease earlier

By Richard Hindle

A new approach to pancreatic cancer screening may help doctors detect the disease in people at high risk before it reaches more advanced and difficult-to treat stages.

Read More

Research reveals mechanism for leukaemia cell growth, prompting new treatment hopes

By Richard Hindle

A mechanism which drives leukaemia cell growth has been discovered by researchers at the University of Sussex, who believe their findings could help to inform new strategies when it comes to treating the cancer.

Read More

Conversion of breast cancer cells into fat cells impedes the formation of metastases

By Richard Hindle

An innovative combination therapy can force malignant breast cancer cells to turn into fat cells. This can be used to prevent the formation of metastases in mice, as researchers at the University of Basel’s Department of Biomedicine recently reported

Read More

Researchers discover common markers of tumour hypoxia across 19 cancer types

By Richard Hindle

Researchers have discovered molecular hallmarks of hypoxia in the first-ever pan-cancer analysis of low oxygen in human tumours. The study investigated more than 8,000 human tumours across 19 different cancer types, this article provides further information.

Read More

Posts pagination

  • Previous
  • 1
  • …
  • 16
  • 17
  • 18
  • Next
Recent Posts
  • Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor
  • Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?
  • Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume
  • Daiichi Sankyo and AstraZeneca does a Batman & Robin act and fires off its second ADC shot of 2024 with another FDA BLA for Dato-DXd
  • Is it time for PET-guided therapy in follicular lymphoma?
×

Error: Contact form not found.

Back To Top

  • Home
  • Team
  • Advisory Services
  • Market Intelligence Services
  • Recruitment
  • Contact
  • Market Access / BD
  • CME Learner Resources
  • CME Evaluation Form
  • Help Centre
  • Contact
  • Disclaimers
  • Privacy & GDPR Policy
  • Website Accessibility Policy
  • Equal Opportunities Policy and Learning Charter
  • Complaints Policy
  • Contact
© Oncology Commercial Services 2025
Built with Storefront.

Copyright 2024  Oncology Commercial Services. All Rights Reserved. Fratrem Group Ltd, Company number 08002465